Q32 Bio

The firm's most advanced candidate is bempikibart, a fully human anti-IL-7Rα monoclonal antibody. It is currently being evaluated in a Phase 2 trial for alopecia areata. The molecule blocks signaling of both IL-7 and thymic stromal lymphopoietin (TSLP), two cytokines that regulate adaptive immune function.

Bempikibart targets the IL-7 receptor alpha chain, simultaneously inhibiting IL-7 and TSLP signaling. This dual blockade is designed to re-regulate T-cell-driven inflammation upstream of many current targets. Most approved autoimmune drugs, such as JAK inhibitors, act further downstream or on different cytokine families.

No. As of its most recent public disclosures available in mid-2026, the firm has not published a fundraising total, named any institutional investors, or confirmed a cash runway. Financial details remain entirely undisclosed.

As of 2025, there are zero FDA-approved therapies for alopecia areata, though late-stage JAK inhibitor programs from other companies have generated significant clinical data. An estimated 700,000 people in the United States live with the disease, creating a substantial commercial opportunity for any therapy that demonstrates disease-modifying efficacy with an acceptable safety profile.

The company's public-facing materials reference only a single program targeting autoimmune and inflammatory diseases. There is no disclosure of preclinical assets, technology platform licenses, or combination approaches.

It is a clinical-stage biotechnology company with no evidence of family-office capitalization or structure. Public records do not link the firm to a single-family wealth origin or multi-family advisory model. Its operational footprint — a Cambridge-based drug development company — aligns with traditional venture-backed or privately funded biotech structures, though funding sources are not disclosed.

Q32 Bio has released minimal public information as of mid-2026: no disclosed team, financials, partners, or trial timelines beyond the existence of a Phase 2 alopecia areata study. The profile reflects only what is confirmable from the firm's own website and public records. Were the firm to complete a financing or data readout, the operational detail would expand considerably.